Atossa Therapeutics: Strategic Endoxifen Opportunity in DMD and PRV Creates Buy-Rated Upside at Disconnected Valuation

Maxim Group analyst Jason McCarthy maintained a Buy rating on Atossa Therapeutics on February 5 and set a price target of $40.00.

Jason McCarthy has given his Buy rating due to a combination of factors including the strategic value of endoxifen in Duchenne muscular dystrophy and the renewed Priority Review Voucher framework. He views endoxifen’s Rare Pediatric Disease designation and its potential eligibility for a high-value PRV as a meaningful economic and strategic catalyst for Atossa, particularly now that the U.S. program has been reauthorized in the recent funding bill.

He also highlights that endoxifen’s oral formulation, established safety from breast cancer studies, and likely progression directly into Phase 2 for DMD create an efficient development path in a competitive, high-value DMD market. With shares down sharply after a reverse split despite an estimated cash runway into 2027, McCarthy interprets current weakness as disconnected from fundamentals and sees it as an attractive entry point ahead of potential upside from the DMD program.